1-methyl-3-(4-pyridin-2-yl-benzyl)thiourea | 1400799-62-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-methyl-3-(4-pyridin-2-yl-benzyl)thiourea
• 英文别名: 1-methyl-3-(4-pyridinyl-2-benzyl)thiourea；1-Methyl-3-(4-pyridin-2-yl-benzyl)-thiourea；1-methyl-3-[(4-pyridin-2-ylphenyl)methyl]thiourea
• CAS: 1400799-62-3
• 化学式: C₁₄H₁₅N₃S
• 分子量: 257.359
• InChiKey: DYHMGGJGZLNZNS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  69
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-(2-吡啶基)-苯甲醛 在 sodium tetrahydroborate 、 titanium(IV)isopropoxide 作用下， 以 四氢呋喃 为溶剂， 生成 1-methyl-3-(4-pyridin-2-yl-benzyl)thiourea
  参考文献：
  名称：

  N-methylthioureas as new agonists of retinoic acid receptor-related orphan receptor

  摘要：

  制备了三十二种硫脲衍生物，并评估了它们对视黄酸受体相关孤儿受体α（RORα）的激动活性。将先导化合物CGP52608（1）的3-烯丙基-2-亚氨基-噻唑烷-4-酮部分替换为各种官能团取代的芳香环，从而提高了RORα的激动活性。在制备的衍生物中，1-甲基-3-（4-苯氧基-苄基）-硫脲（32）在RORα激活试验中显示出比CGP52608高2.6倍的激动活性。

  DOI：

  10.1007/s12272-012-0809-0

文献信息

• NOVEL THIOUREA DERIVATIVES AS ACTIVATORS OF RORalpha AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
  申请人：LEE Mi Ock

  公开号：US20180265462A1

  公开（公告）日：2018-09-20

  Provided is a compound activating RORα gene, particularly a JC1 compound containing CGP52608 thiazolidinedione as a lead substance, and a pharmaceutically acceptable salt thereof. The compound is a lipid accumulation inhibitor and applicable to the treatment of metabolic diseases or inflammatory diseases.

  提供的是一种激活RORα基因的化合物，特别是一种含有CGP52608噻唑烷二酮作为主要物质的JC1化合物，以及其药用盐。该化合物是一种脂肪积聚抑制剂，适用于治疗代谢性疾病或炎症性疾病。
• PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AUTOIMMUNE DISEASES COMPRISING THIOUREA DERIVATIVE
  申请人：SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION

  公开号：US20180235912A1

  公开（公告）日：2018-08-23

  The present invention relates to a novel use of a thiourea derivative and, more specifically, to a pharmaceutical composition for preventing or treating autoimmune diseases comprising a thiourea derivative as an active ingredient. The thiourea derivative according to the present invention can inhibit the transcription of inflammatory genes such as TNF-α, IL-1β, NOS2 and IL-6, and also can inhibit the activity or production of Th17 and increase the activity or production of a regulatory T cell (Treg). Thus, it is expected that the thiourea derivative may be usefully used in a pharmaceutical composition, a health food composition, etc. for the prevention, improvement or treatment of various autoimmune diseases including rheumatoid arthritis.